Company intelligence / Profile preview

Atlas Partners

Cambridge, Massachusetts, United Statesatlaspartners.com ↗

Ownership: Private
Employees: ~157
Development stage: Other

Overview

Over its history, more than 25 medicines developed by its portfolio have reached patients. Recent highlights include major IPOs and acquisitions—e.g., Nimbus’ TYK2 program acquired by Takeda for $4B upfront; Versanis Bio acquired by Eli Lilly for up to $1.925B; Intellia’s CRISPR program entering Phase III trials. Day One Biopharmaceuticals achieved FDA approval for Ojemda™ for pediatric low-grade glioma.

Therapeutic areas: OncologyRare DiseasesImmunologyHematologyOphthalmologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibodyGene therapyRNA therapyRadiopharmaceuticalsCell therapy
Industry: Investors

Beyond the preview

Go deeper on Atlas Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atlas Partners.

Explore the full profile